Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 Junho 2023 - 7:00AM
Business Wire
Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”),
an innovative, near clinical-stage biopharmaceutical company that
develops novel, miniature, long-term therapeutic implants,
announced today that Company CEO Adam Mendelsohn, Ph.D. has been
invited to participate at the Healthcare Virtual Conference Part
II, presented by Maxim Group LLC and hosted by M-Vest. Dr.
Mendelsohn will participate in the panel discussion entitled “Oh!
Oh! Ozempic - Metabolics are in Focus” on June 20 at 11:00 am
ET.
The exponential growth in knowledge and expertise in science and
medicine continues to drive opportunities in the healthcare space.
These include multiple therapeutic categories and emerging
technologies, which Maxim’s presenting companies at this year’s
Maxim Healthcare Conference are focused on, and for many, that
includes key data-driven events in 2023. Maxim Senior Analysts will
host a wide range of biotechnology and medical device companies in
a series of presentations and interactive discussions with CEOs and
key management. Maxim will also be hosting several topical industry
panels that promise to be timely and engaging.
This conference, which takes place June 20-22, will be
accessible live on M-Vest. To attend, please sign up to become an
M-Vest member.
Click Here to Reserve your seat
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal platform, Vivani Medical
develops biopharmaceutical implants designed to deliver drug
molecules steadily over extended periods of time, with the goal of
guaranteeing patient adherence and potentially improving
tolerability to their medication. Vivani’s lead program, NPM-119,
is a miniature, 6-month GLP-1 implant under investigation for the
treatment of patients with Type 2 diabetes and/or obesity. NPM-119
can provide patients the opportunity to realize the full potential
benefit of their medication while avoiding the hassles associated
with the daily or weekly administration of oral and injectable
products. Medication non-adherence occurs when patients do not take
their medication as prescribed. This affects an alarming number of
patients, approximately 50%, including those taking daily pills.
Medication non-adherence and poor tolerability are main reasons why
Type 2 diabetes and/or obesity treatments face challenges in
achieving optimal real-world effectiveness.
Vivani represents the August 2022 merger of Second Sight Medical
Products, Inc., and Nano Precision Medical, Inc. NPM-119 (GLP-1
implant) remains the top priority for the combined company and an
Investigational New Drug application remains on track for filing
with the US Food and Drug Administration (FDA) in 2023 to support
initiation of a Phase 2 clinical study called LIBERATE-1. Vivani is
also developing a portfolio of innovative, highly differentiated,
new drug products leveraging its proprietary NanoPortal implant
technology, which has potential application across a broad range of
compounds including peptide therapeutics. For more information,
please visit www.vivani.com.
Vivani subsidiary Cortigent Inc. was formed to continue the
business of Second Sight Medical Products, a pioneer in developing
targeted neurostimulation systems to help patients recover critical
body functions including profound blindness and the recovery of arm
and hand function in patients who are partially paralyzed due to
stroke. Cortigent has publicly filed a registration statement on
Form S-1 with the U.S. Securities and Exchange Commission (“SEC”)
relating to a proposed initial public offering of its common stock.
Cortigent intends to list its common stock on the Nasdaq Capital
Market under the ticker symbol “CRGT.” A registration statement
relating to the proposed offering has been filed with the SEC but
has not yet become effective. These securities may not be sold, nor
may offers to buy be accepted, prior to the time the Registration
Statement becomes effective. This press release does not constitute
an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offers,
solicitations or offers to buy, or any sales of securities will be
made in accordance with the registration requirements of the
Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains certain “forward-looking statements”
within the meaning of the “safe harbor” provisions of the US
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “target,” “believe,”
“expect,” “will,” “may,” “anticipate,” “estimate,” “would,”
“positioned,” “future,” and other similar expressions that in this
press release, including statements regarding our business,
products under development, including the therapeutic potential
thereof and the planned development therefor, technology and
strategy. Forward-looking statements are neither historical facts
nor assurances of future performance. Instead, they are based only
on our current beliefs, expectations, and assumptions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Actual results and outcomes may differ materially from
those indicated in the forward-looking statements. Therefore, you
should not rely on any of these forward-looking statements.
Important factors that could cause actual results and outcomes to
differ materially from those indicated in the forward-looking
statements include, among others, risks related to the development
and commercialization of our product under development, including
NPM-119; delays and changes in applicable laws, regulations and
guidelines including potential delays in submitting required
regulatory applications to the U.S. Food and Drug Administration
(“FDA”); risks related to the initiation, enrollment and conduct of
our planned clinical trials and the results therefrom; our history
of losses and our ability to achieve or sustain profitability in
the future; and the impact of COVID-19 on our business. There may
be additional risks that the Company considers immaterial, or which
are unknown. A further list and description of risks and
uncertainties can be found in the Company’s most recent Annual
Report on Form 10-K, and any subsequent quarterly filings on Form
10-Q filed with the Securities and Exchange Commission (the
“Commission”). Any forward-looking statement made by us in this
press release is based only on information currently available to
the Company and speaks only as of the date on which it is made. The
Company undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of added information,
future developments or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230614641511/en/
Company Contact: Donald Dwyer Chief Business Officer
info@vivani.com (415) 506-8462
Investor Relations Contact: Brigid Makes Chief Financial Officer
investors@vivani.com (415) 506-8462
Media Contact: Sean Leous ICR Westwicke Sean.Leous@westwicke.com
(646) 866-4012
Vivani Medical (NASDAQ:VANI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Vivani Medical (NASDAQ:VANI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024